Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran
US Decision Expected Before 2020 Ends
Sep 01 2020
•
By
Andrew McConaghie
Novartis is counting on inclisuran to be a blockbuster after its $9.7bn buyout of the drug's developer, The Medicines Company
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
More from Business
More from Scrip